title: [Management of unresectable non-metastatic non-small cell lung cancer. Guidelines of clinical practice made by the European Lung Cancer Working Party].
abstract: The present updated guidelines on the management of unresectable non-metastatic nonsmall cell lung cancer (NSCLC) formulated by the ELCWP are designed to answer the following questions: 1) Is chest irradiation curative for NSCLC? 2) What are the contra-indications (anatomical or functional) to chest irradiation ? 3) Does the addition of chemotherapy add any advantage to radiotherapy? 4) Does the addition of radiotherapy add any advantage to chemotherapy? 5) In marginally resectable stage III is irradiation as effective as surgery? 6) How to best combine chemotherapy with radiotherapy: sequentially, concomitantly, as consolidation, as induction, as radiosensitiser? 7) In case of too advanced locoregional disease, is there a role for consolidation (salvage) local treatment (surgery, radiotherapy) after induction chemotherapy? 8) In 2014, what are the technical characteristics of an adequate radiotherapy? 9) What treatment for the patient unfit to receive a radical multimodal treatment based on radiotherapy? 10) Have targeted therapies a role? 11) What indication for preventive brain irradiation (PCI)?
authors.forename: M
authors.initials: M
authors.lastname: Paesmans
mesh_terms: D001932:Brain Neoplasms / Q000517:prevention & control; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods; D005060:Europe; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods; D016896:Treatment Outcome